NEITHER CANCER NOR MYOSITIS ARE COMMON IN PATIENTS TESTING POSITIVE FOR TIF1. BY LINE IMMUNOBLOT ASSAY

被引：0
|
作者：
Troelnikov, Alexander [1 ,2 ]
Choo, Xin Jing [3 ]
Beroukas, Dimi [1 ]
Limaye, Vidya [3 ,4 ]
机构：
[1] SA Pathology, Immunopathol Dept, Adelaide, SA, Australia
[2] Flinders Univ S Australia, Adelaide, SA, Australia
[3] Univ Adelaide, Discipline Med, Adelaide, SA, Australia
[4] Royal Adelaide Hosp, Dept Rheumatol, Adelaide, SA, Australia
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2023年 / 41卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P-42
引用
收藏
页码：455 / 455
页数：1
相关论文
共 50 条
  • [1] Neither cancer nor myositis are common in patients testing positive for anti-TIF1γ by line blot in real-world laboratory settings
    Troelnikov, Alexander
    Choo, Xin Jing
    Beroukas, Dimitra
    Limaye, Vidya
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2023, 26 (03) : 586 - 590
  • [2] Myopathological features of cancer-free myositis with anti-TIF1-γ-Ab positive
    Taira, Kenichiro
    Uchio, Naohiro
    Unuma, Atsushi
    Kadoya, Masato
    Ikenaga, Chiseko
    Kubota, Akatsuki
    Shimizu, Jun
    Toda, Tatsushi
    BRAIN PATHOLOGY, 2019, 29 : 32 - 32
  • [3] Analysis of the risk of cancer among myositis patients without anti-TIF1-γ OR -HMGCR antibodies
    Unuma, A.
    Kadoya, M.
    Hida, A.
    Taira, K.
    Uchio, N.
    Ikenaga, C.
    Kubota, A.
    Tsuji, S.
    Shimizu, J.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 268 - 268
  • [4] Positive predictive value of myositis antibody line blot testing in patients with suspected idiopathic inflammatory myopathy
    Chang, Yiu-Chia
    Yang, Liju
    Budhram, Adrian
    MUSCLE & NERVE, 2024, 69 (05) : 626 - 630
  • [5] A KEY TIF1Γ EPITOPE MAY FACILITATE THE IDENTIFICATION OF PATIENTS AT HIGHEST RISK OF CANCER ASSOCIATED MYOSITIS
    Riddell, V.
    Mcmorrow, F.
    Oldroyd, A.
    Deakin, C.
    Lamb, J.
    Chinoy, H.
    Wedderburn, L.
    Bagby, S.
    Mchugh, N.
    Tansley, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 369 - 370
  • [6] A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing
    Mulhearn, Ben
    Li, Danyang
    McMorrow, Fionnuala
    Lu, Hui
    McHugh, Neil J.
    Tansley, Sarah L.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [7] Machine Learning Algorithms Identify Clinical Subtypes and Cancer in Anti-TIF1γ+ Myositis: A Longitudinal Study of 87 Patients
    Zhao, Lijuan
    Xie, Shuoshan
    Zhou, Bin
    Shen, Chuyu
    Li, Liya
    Pi, Weiwei
    Gong, Zhen
    Zhao, Jing
    Peng, Qi
    Zhou, Junyu
    Peng, Jiaqi
    Zhou, Yan
    Zou, Lingxiao
    Song, Liang
    Zhu, Honglin
    Luo, Hui
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [8] NOVEL BIOMARKERS PREDICT WHETHER CANCER EMERGES IN ANTI-TIF1-G POSITIVE DM PATIENTS AT HIGH RISK FOR CANCER
    Casciola-Rosen, Livia
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 408 - 408
  • [9] Anti-Sp4 and anti-CCAR1 autoantibodies in UK vs US patients with adult and juvenile-onset anti-TIF1γ-positive myositis
    McMorrow, Fionnuala K.
    Wedderburn, Lucy R.
    Chinoy, Hector
    Oldroyd, Alexander
    Lamb, Janine A.
    Rider, Lisa G.
    Mammen, Andrew L.
    Casciola-Rosen, Livia
    McHugh, Neil J.
    Tansley, Sarah L.
    RHEUMATOLOGY, 2024,
  • [10] Therapeutic attitude in patients with positive resection line involvement (R1) after gastrectomies for gastric cancer
    Nicolescu, N.
    Molnar, G.
    Iancu, C.
    Al Hajjar, N.
    Bala, O.
    Munteanu, D.
    Vlad, L.
    CHIRURGIA, 2011, 106 (01) : 33 - 36
12345